Suspension of trading
Oncternal Therapeutics, Inc. Stock
Stocks
ONCT
US68236P2065
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5266 USD | -24.11% |
|
-.--% | - |
| 01/07/25 | Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO | CI |
| 01/07/25 | Oncternal Therapeutics, Inc. Announces Management Changes | CI |
| Market Cap | 1.56M 1.35M 1.26M 1.15M 2.17M 148M 2.21M 14.77M 5.8M 74.35M 5.85M 5.72M 246M | P/E 2022 |
-1.19x | P/E 2023 | -0.8x |
|---|---|---|---|---|---|
| Enterprise Value | -32.38M -28.01M -26.15M -23.99M -45.13M -3.08B -45.84M -307M -120M -1.54B -122M -119M -5.11B | EV / Sales 2022 |
-4.9x | EV / Sales 2023 | -2.95x |
| Free-Float |
90.77% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | -24.11% |
| 3 years | 0.53 |  | 13.14 |
| 5 years | 0.53 | | 92.6 |
| 10 years | 0.53 | | 211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Vincent
DFI | Director of Finance/CFO | 63 | 01/04/2017 |
Yisrael Katz
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
Rajesh Krishnan
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Hale
CHM | Chairman | 77 | 01/12/2018 |
Dan Kisner
BRD | Director/Board Member | 79 | 07/06/2019 |
William LaRue
BRD | Director/Board Member | 75 | 01/12/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 20/6/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/6/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/6/24 | Free | Director | 2,200 | 0.0743% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -24.11% | -.--% | -.--% | -91.95% | 1.56M | |
| +0.99% | +1.78% | +4.07% | +16.73% | 49.47B | |
| +3.71% | +9.40% | +486.98% | +592.14% | 43.61B | |
| +5.60% | +10.21% | +16.76% | +85.72% | 39.6B | |
| +2.70% | +1.57% | +33.39% | +8.85% | 39.29B | |
| +2.21% | +6.75% | +21.31% | +53.37% | 32.43B | |
| +2.23% | +4.71% | - | - | 16.84B | |
| +0.97% | +2.35% | +37.75% | +126.84% | 16.49B | |
| -0.11% | +2.41% | +6.24% | +18.87% | 14.01B | |
| +0.75% | +15.04% | +78.59% | +30.30% | 12.77B | |
| Average | -0.51% | +3.10% | +76.12% | +93.43% | 26.45B | |
| Weighted average by Cap. | +2.54% | +6.10% | +104.25% | +140.78% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 1.49M 1.29M 1.2M 1.1M 2.08M 142M 2.11M 14.12M 5.54M 71.08M 5.6M 5.47M 235M | 785K 679K 634K 582K 1.09M 74.71M 1.11M 7.44M 2.92M 37.45M 2.95M 2.88M 124M |
| Net income | -44.17M -38.21M -35.68M -32.73M -61.56M -4.2B -62.54M -419M -164M -2.11B -166M -162M -6.97B | -39.48M -34.15M -31.89M -29.25M -55.02M -3.76B -55.9M -374M -147M -1.88B -148M -145M -6.23B |
| Net Debt | -63.64M -55.05M -51.4M -47.16M -88.69M -6.06B -90.1M -603M -237M -3.04B -239M -234M -10.04B | -33.94M -29.36M -27.41M -25.15M -47.3M -3.23B -48.05M -322M -126M -1.62B -127M -125M -5.35B |
Employees
29
- Stock Market
- Stocks
- ONCT Stock
Select your edition
All financial news and data tailored to specific country editions
